https://www.wsj.com/articles/drug-shortages-price-controls-government-fda-white-house-cancer-treatments-b2d08ba4
Politicians like to grouse about high drug prices. Well, now we’re seeing what happens when drug prices are too low: Shortages of essential medicines, which are a portent of what’s to come with the Inflation Reduction Act’s price controls.
Drug shortages aren’t new, but the number in short supply has grown as generic prices have fallen. The American Society of Health-System Pharmacists lists 301 drugs in short supply, up from 202 five years ago. These include many local anesthetics, basic hospital drugs, chemotherapy drugs and liquid albuterol for lung ailments.
The American Cancer Society warned this month that “first-line treatments for a number of cancers, including triple-negative breast cancer, ovarian cancer and leukemia often experienced by pediatric cancer patients,” are facing shortages that “could lead to delays in treatment that could result in worse outcomes.” Healthcare providers say they’re having to limit access to some drugs to the sickest patients. They can substitute therapeutic alternatives when possible, but this increases risk of medication errors and inferior results. What’s going on?
Headlines have focused on shortages of the ADHD drug Adderall and new weight-loss treatments, which owe to increased demand. But most drugs in short supply are older generics that are off-patent and complicated to make. Manufacturers have stopped producing them because profit margins are too thin, resulting in one or two suppliers.